From FDA actions to new standard-of-care potential, the breast cancer treatment arsenal continues to expand. This week’s news ...

Data from the COMMIT trial demonstrated that the addition of oxaliplatin, leucovorin, 5-fluorouracil (mFOLFOX6) and ...

About 15,000 registered nurses at several of New York City’s major hospitals walked off the job Jan 12 after contract ...

When a patient with renal cell carcinoma (RCC) progresses on or following the combination of a tyrosine kinase inhibitor (TKI ...

Data from the longitudinal ColoCare study (NCT02328677) of patients with colorectal cancer add to a growing body of evidence ...

We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Riley Kandel | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 inhibitors at community clinics.

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.